AI Science Tracker

Zhejiang Cancer Hospital

2 discoveries from 2023 to 2025

Discoveries

A six-metabolite machine-learning panel and isovalerylcarnitine findings for gastric cancer

In two multicenter cohorts totaling 597 people, LASSO feature selection and five machine-learning classifiers produced a six-metabolite plasma panel for gastric-cancer diagnosis, with AUCs of 0.947–0.982 in discovery and 0.920–0.951 in validation. The panel included isovalerylcarnitine (C5), which was lower in cancer plasma and paired tumor tissue; the paper further reported a Mendelian-randomization association and cell-assay evidence linking C5 treatment to reduced gastric-cancer cell migration and invasion through calpain-associated changes in VE-cadherin and MMP2.

Technology: LASSO regression score feature selection with neural-network, support-vector-machine, ridge-regression, logistic-regression and naive-Bayes classifiers

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: In two multicenter cohorts totaling 597 people, LASSO feature selection and five machine-learning classifiers produced a six-metabolite plasma panel for gastric-cancer diagnosis, with AUCs of 0.947–0.982 in discovery and 0.920–0.951 in validation.
  • Still unknown: The cohorts were case-control clinical samples and do not establish population-screening performance or improved patient outcomes. The validation cohort contained 453 participants from seven centers; no prospective care-impact trial was reported. Mendelian-randomization evidence is observational genetic-instrument analysis, and cell migration/invasion experiments do not establish a treatment effect in animals or people. The 2024 IDDF abstract (DOI 10.1136/gutjnl-2024-IDDF.267) is an earlier disclosure of this same project, not a separate discovery. Source checked; independent replication not assessed.
  • AI role: Machine-learning feature selection narrowed replicated plasma metabolite signals to a six-feature diagnostic panel, and the specified classifiers constructed/evaluated diagnostic models. The C5 mechanistic work was follow-up metabolomics, Mendelian-randomization, proteomic-correlation and in-vitro experimentation; the record does not imply that machine learning alone established the mechanism.

Evidence sources: https://link.springer.com/article/10.1038/s44321-025-00325-0

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 86 of works of the same type, year and subfield (OpenAlex work metrics, 9 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Machine-learning analysis of plasma metabolomic fingerprints yields a 21-metabolite gastric-cancer panel validated across multicentre cohorts

In a multicentre study, machine-learning analysis of plasma metabolic fingerprints from 1,944 retrospective participants selected a 21-metabolite panel that differentiated gastric-cancer from non-cancer cohorts; five model types achieved AUCs of 0.921–0.971 in discovery and 0.907–0.940 in external verification. Prospective testing in 264 participants using both NPELDI-MS and UPLC-MS reported diagnostic AUCs of 0.855–0.918 and 0.856–0.916, respectively. The paper also reports a four-metabolite prognostic score based on retrospective survival data.

Technology: Neural network, lasso regression, ridge regression, support-vector machine and random-forest models applied to plasma metabolic fingerprints

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: prospective or independent check
  • Tested: In a multicentre study, machine-learning analysis of plasma metabolic fingerprints from 1,944 retrospective participants selected a 21-metabolite panel that differentiated gastric-cancer from non-cancer cohorts; five model types achieved AUCs of 0.921–0.971 in discovery and 0.907–0.940 in external verification.
  • Still unknown: The panel was evaluated in selected clinical cohorts and is not established for routine screening or clinical use. Prospective validation was at one lead center, and only six panel metabolites were robustly detected by confirmatory UPLC-MS under the reported testing. Model performance does not show that the panel is causal or improves outcomes. Primary full text/abstract checked; no independent replication assessed.
  • AI role: The study used machine-learning feature selection/modeling (including logistic-regression coefficient filtering) to identify and evaluate a 21-metabolite diagnostic panel from high-throughput mass-spectrometry fingerprints; classifiers were then validated on independent retrospective and prospective cohorts.

Evidence sources: https://gut.bmj.com/content/72/11/2051

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 95 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.